- Culture of innovation;
- Proven track record of incubating internal unicorns;
- A portfolio of businesses that leverage each other's strength
Company Introduction
Genscript Biotech Corporation (the "Company" or "GenScript", together with its subsidiaries, the "Group") is a well-recognised biotechnology company. Based on our proprietary gene synthesis technology and the other technology and know-hows on life-science research and application, we have four well established major platforms including (i) a leading life-science services and products platform to provide one-stop solutions to global research communities, (ii) a biologics contract development and manufacturing organization (the "CDMO") platform, (iii) an industrial synthetic products platform, and (iv) an integrated global cell therapy platform. The above four internally built platforms have demonstrated their strong growth from research and development to commercial delivery for year ended December 31, 2020 respectively. Read More »
The Group has been inspired by the mission "Make People and Nature Healthier through Biotechnology" since it was founded 18 years ago. Our clients' business need is the Group's first priority and the ultimate cornerstone for pursuing its long term development. We have been improving our clients' competitiveness through providing our superior quality, fast-delivery and cost-effective services and products. Internally, we focus on streamlining our operational workflows and procedures with the aim to strive for the highest quality of end-to-end delivery. Externally, we actively promote the value of strategic collaboration with business partners with the vision to build up a healthy biotech eco-system. We would like to contribute more of our efforts to speed up the evolution of the whole biotech and biopharma industry, to realize multi-win among all the participating partners in this industry.
Platform Company
Global Business
- 100K+ customers in over 100 countries;
- Global Sales, Manufacturing and R&D presence in US, Europe and Asia Pacific
Strong IP Position
- Proprietary technology across all business lines;
- Over 140 granted patents and over 500 patent applications
Highly Skilled Workforce
- 4600+ employees globally;
- Over 78% of employees hold Bachelor & above degrees;
- Over 39% of employees hold Master & above degrees;
* As of June 30th, 2020
Company History
- cPass™ SARS-CoV-2 neutralization antibody detection kit widely applied worldwide and receiving US FDA's authorization in convalescent plasma screening
- EMA accepted a request for an accelerated assessment for Legend's CAR-T therapy
- Won "Best CRO Award APAC" by IMAPAC
- Hillhouse Group Investment
- Developed the world's first cPass™ SARS-CoV-2 with Singapore to jointly fight COVID-19
- Legend Biotech listed on NASDAQ
- Cell therapy was granted China's first "breakthrough therapy designation"
- The Group's biopharmaceutical CDMO business officially launches its brand, ProBio
- Launched New Biologics GMP CDMO R&D center;
- Established European & Asia-Pacific Division
- BCMA program received Orphan Drug Designation (FDA) & PRIME Designation (EMA)
- BCMA Program received IND clearance in US and China
- Biologics CDMO segment officially established
- Legend and Janssen entered into collaboration on BCMA program
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- GenScript Biotech listed in HKEX (Stock code:1548)
- Launched Legend Biotech (the Cell Therapy Segment)
- CRO Leadership award
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- New research and production facility opened in Nanjing
- Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project
- Established subsidiary in Japan
- KPCB / TBIG Healthcare investment
- Introduced Custom Protein and Antibody Service
- Established research and production center in Nanjing, China
- GenScript Founded in New Jersey，US
Business Positioning
Life Science Services and Products
Biologics Development & Manufacturing
Synthetic Biology
Cell Therapy
Key Facts
Citations Database
Frequently-Cited in Publications: As of June 30, 2022, GenScript's products and services have been cited by 74,700 peer-reviewed journal articles worldwide; placing GenScript among the most frequently-cited biotech companies in the world.
Life Science
Proven Gene Expertise: As the leading gene synthesis provider in the world, our gene synthesis tools are designed to make research accessible. Our propriety, population immune algorithm based GenSmart codon optimization technology enables the design of the most expression-efficient sequence available, while our CloneArk™ system provides a platform for researchers to archive, share and reuse their clones for future use with peace of mind.
Reliable Synthetic Peptides: Powered by advanced PepPower™ synthesis technology platform and supported by stringent quality management systems, GenScript synthesizes more than 25,000 peptides/month, featured with variety of custom modifications, delivery options, and high level of batch-to-batch consistency.
Proprietary MonoRab™ Antibody: Powered by a unique B-cell cloning protocol, GenScript allows our clients to test for antibodies that work in their application before sequencing the desired clones for recombinant antibody production. Work with us to generate exclusive, custom rabbit monoclonal antibodies that are high in sensitivity, affinity and specificity for your research and diagnostic needs.
Premier High-Throughput Gene to Antibody Production: Designed to accelerate the drug screening process, GenScript helps researchers identify promising candidate leads and advance to the production of purified recombinant antibodies with one of the fastest turnaround times in the industry.
Licensed CRISPR/Cas9 Genome Editing: Through partnership with the technology's pioneering Broad Institute of MIT and Harvard, as well as ERS Genomics, GenScript offers a variety of CRISPR services, including guide RNA design tools, pre-validated CRISPR plasmids, and learning resources to help scientists harness the power of CRISPR genome editing in life science research.
